Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, Version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(11):1362–1389. doi:10.6004/jnccn.2018.0083
   PubMed Web of Science ®Google Scholar
• Schünemann HJ, Lerda D, Quinn C, et al. Breast cancer screening and diagnosis: a synopsis of the european breast guidelines. Ann Intern Med. 2020;172(1):46–56. doi:10.7326/M19-2125
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–1747. doi:10.1093/annonc/mdr304
   PubMed Web of Science ®Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–1546. doi:10.1093/annonc/mdv221
   PubMed Web of Science ®Google Scholar
• Curigliano G, Criscitiello C. Maximizing the clinical benefit of anthracyclines in addition to taxanes in the adjuvant treatment of early breast cancer. J Clin Oncol. 2017;35(23):2600–2603. doi:10.1200/JCO.2017.72.5960
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao B, Jin F. The assessment of 8th edition AJCC prognostic staging system and a simplified staging system for breast cancer: the analytic results from the SEER database. Breast J. 2019;25(5):838–847. doi:10.1111/tbj.13347
   PubMed Web of Science ®Google Scholar
• Yu Y, Tan Y, Xie C, et al. Development and validation of a preoperative magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with early-stage breast cancer. JAMA Netw Open. 2020;3(12):e2028086. doi:10.1001/jamanetworkopen.2020.28086
   PubMed Web of Science ®Google Scholar
• Liu D, Wu J, Lin C. Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a population-based study. Front Oncol. 2020;10:580112. doi:10.3389/fonc.2020.580112
   PubMed Web of Science ®Google Scholar
• Cui X, Zhu H, Huang J. Nomogram for predicting lymph node involvement in triple-negative breast cancer. Front Oncol. 2020;10:608334. doi:10.3389/fonc.2020.608334
   PubMed Web of Science ®Google Scholar
• Kim S, Takahashi H, Lin -W-W, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102–106. doi:10.1038/nature07623
   PubMed Web of Science ®Google Scholar
• Mantovani A. Cancer: inflaming metastasis. Nature. 2009;457(7225):36–37. doi:10.1038/457036b
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540. doi:10.1016/j.ctrv.2012.08.003
   PubMed Web of Science ®Google Scholar
• Zhang N, Ning F, Guo R, et al. Prognostic values of preoperative inflammatory and nutritional markers for colorectal cancer. Front Oncol. 2020;10:585083. doi:10.3389/fonc.2020.585083
   PubMed Web of Science ®Google Scholar
• Toyokawa T, Muguruma K, Yoshii M. Clinical significance of prognostic inflammation-based and/or nutritional markers in patients with stage III gastric cancer. BMC Cancer. 2020;20(1):517. doi:10.1186/s12885-020-07010-0
   PubMed Web of Science ®Google Scholar
• Sandfeld-Paulsen B, Meldgaard P, Sorensen BS. The prognostic role of inflammation-scores on overall survival in lung cancer patients. Acta Oncol. 2019;58(3):371–376. doi:10.1080/0284186X.2018.1546057
   PubMed Web of Science ®Google Scholar
• Moldoveanu D, Pravongviengkham V, Best G, et al. Dynamic neutrophil-to-lymphocyte ratio: a novel prognosis measure for triple-negative breast cancer. Ann Surg Oncol. 2020;27(10):4028–4034. doi:10.1245/s10434-020-08302-2
   PubMed Web of Science ®Google Scholar
• Yoon CI, Kim D, Ahn SG, et al. Radiotherapy-induced high neutrophil-to-lymphocyte ratio is a negative prognostic factor in patients with breast cancer. Cancers. 2020;12(7):1896. doi:10.3390/cancers12071896
   PubMed Web of Science ®Google Scholar
• Gilmore N, Mohile S, Lei L, et al. The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy. Breast Cancer Res. 2021;23(1):19.
   PubMed Web of Science ®Google Scholar
• Van Berckelaer C, Vermeiren I, Vercauteren L, et al. The evolution and prognostic role of tumour-infiltrating lymphocytes and peripheral blood-based biomarkers in inflammatory breast cancer patients treated with neoadjuvant chemotherapy. Cancers. 2021;13(18):4656. doi:10.3390/cancers13184656
   PubMed Web of Science ®Google Scholar
• Zhou L, Ma S, Balde AI, et al. A retrospective propensity score matched study of the preoperative c-reactive protein to albumin ratio and prognosis in patients with resectable non-metastatic breast cancer. Med Sci Monit. 2019;25:4342–4352.
   PubMed Web of Science ®Google Scholar
• Moro-García MA, Mayo JC, Sainz RM, et al. Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes. Front Immunol. 2018;9:339. doi:10.3389/fimmu.2018.00339
   PubMed Web of Science ®Google Scholar
• Sproston NR, Ashworth JJ. Role of C-Reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. doi:10.3389/fimmu.2018.00754
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, et al. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180. doi:10.1016/S1470-2045(14)71116-7
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar
• Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–1366. doi:10.1200/JCO.19.02309
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105–2122. doi:10.1200/JCO.2018.77.8738
   PubMed Web of Science ®Google Scholar
• Kassambara A, Kosinski M, Biecek P, et al. Package “survminer”. Available from: https://cran.r-project.org/web/packages/survminer/survminer.pdf. Accessed February 26, 2020.
   Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Garber K. First results for agents targeting cancer-related inflammation. J Natl Cancer Inst. 2009;101(16):1110–1112. doi:10.1093/jnci/djp266
   PubMedGoogle Scholar
• Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–596. doi:10.1038/nrclinonc.2015.105
   PubMed Web of Science ®Google Scholar
• Gkretsi V, Zacharia LC, Stylianopoulos T. Targeting inflammation to improve tumor drug delivery. Trends Cancer. 2017;3(9):621–630. doi:10.1016/j.trecan.2017.07.006
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–998. doi:10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Kuscuoglu D, Janciauskiene S, Hamesch K, et al. Liver - master and servant of serum proteome. J Hepatol. 2018;69(2):512–524. doi:10.1016/j.jhep.2018.04.018
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. 2020;272(2):342–351. doi:10.1097/SLA.0000000000003239
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Y, Ni J, et al. Prognostic value of lymphocyte-C-Reactive protein ratio in patients undergoing radical cystectomy for bladder cancer: a population-based study. Front Oncol. 2021;11:760389. doi:10.3389/fonc.2021.760389
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Fujikawa H, et al. Prognostic potential of lymphocyte-C-Reactive protein ratio in patients with rectal cancer receiving preoperative chemoradiotherapy. J Gastrointest Surg. 2021;25(2):492–502. doi:10.1007/s11605-019-04495-4
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564. doi:10.1126/science.1203543
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–284. doi:10.1038/nrc2622
   PubMed Web of Science ®Google Scholar
• Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015;523(7560):313–317. doi:10.1038/nature14583
   PubMed Web of Science ®Google Scholar
• Zheng Z-Y, Bay B-H, Aw S-E, et al. A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells. J Biol Chem. 2005;280(17):17480–17487. doi:10.1074/jbc.M501261200
   PubMed Web of Science ®Google Scholar
• Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279. doi:10.1371/journal.pmed.1000279
   PubMed Web of Science ®Google Scholar
• Pichon MF, Pallud C, Brunet M, et al. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980;40(9):3357–3360.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Viale G, Cabiddu M, et al. Prognost ic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477–491. doi:10.1007/s10549-015-3559-0
   PubMed Web of Science ®Google Scholar
• De AE, Cardoso F, de Castro GJ, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 2007;96(10):1504–1513. doi:10.1038/sj.bjc.6603756
   PubMed Web of Science ®Google Scholar
• Peng Y, Chen R, Qu F, et al. Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients. Cancer Biol Ther. 2020;21(2):189–196. doi:10.1080/15384047.2019.1680057
   PubMed Web of Science ®Google Scholar
• Sun L, Brentnall A, Patel S, et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. AMA Oncol. 2019;5(12):1718–1730.
   Web of Science ®Google Scholar